Barranquilla based pharmaceutical manufacturer Procaps (NASDAQ: PROC) announced that effective February 1st, Melissa Angelini (above) will assume the role of Investor Relations Director, reporting to CFO Patricio Vargas.
“Melissa brings a broad range of investor relations and capital markets experience at pharma companies that will benefit Procaps as we accelerate the delivery of our innovative pharmaceutical solutions and drive new expansion initiatives. Importantly, this new position will eventually be based out of our Aventura, Florida location as we expand our footprint in the U.S.,” said Vargas. “Melissa is a deeply experienced and respected investor relations professional, and her expertise working to communicate our strategy and growth opportunities externally will be instrumental as we continue to strengthen our investor and industry relationships with key stakeholders.”
According to Procaps, Angelini previously served as Innovation & Investor Relations Officer at Brazilian multinational pharmaceutical company Blau Farmacêutica, and was also LATAM Head of Alliance Management & Investor Relations at healthcare firm GBT Grupo Biotoscana where she co-led the IPO of the group in 2017 through a $429 million USD deal.
Angelini was also Investor Relations Client Executive Manager at investor relations firm MZ Group, where she was responsible for the Investor Relations and Strategic Partnerships Department. Angelini holds an MBA in Finance from Insper Instituto de Ensino e Pesquisa, Brazil, and is fluent in English, Spanish and Portuguese.
“I am honored to be joining Procaps at such an exciting inflection point for the company. With their recent entrance to the U.S. on Nasdaq, and announcement of expanded production capacity in the U.S., I will be highly focused on communicating the Procaps story to a broadening group of worldwide investors and shareholders,” said Angelini in a statement.